53,890 Arcutis Biotherapeutics, Inc. $ARQT Shares Purchased by Candriam S.C.A.

Key Points

• Candriam S.C.A. increased its Arcutis Biotherapeutics stake by 5.7%, buying 53,890 shares in the third quarter. It held 1,003,729 shares, valued at about $26.6 million, at the end of the period.
• Arcutis reported quarterly EPS of $0.06, below the $0.18 consensus estimate, while revenue of $143.92 million slightly exceeded forecasts.
• The company raised its 2026 sales guidance and started enrolling patients in a Phase 3 ZORYVE study for atopic dermatitis, providing potential growth catalysts.

Candriam S.C.A. grew its stake in Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report) by 5.7% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,003,729 shares of the company's stock after purchasing an additional 53,890 shares during the period. Candriam S.C.A. owned about 0.80% of Arcutis Biotherapeutics worth $26,625,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Arcutis Biotherapeutics in the third quarter valued at about $36,000. Nykredit A S bought a new position in Arcutis Biotherapeutics during the second quarter valued at about $63,000. Integrated Wealth Concepts LLC bought a new position in Arcutis Biotherapeutics during the second quarter valued at about $84,000. Sterling Capital Management LLC raised its holdings in Arcutis Biotherapeutics by 839.3% in the 3rd quarter. Sterling Capital Management LLC now owns 3,776 shares of the company's stock valued at $100,000 after acquiring an additional 3,374 shares in the last quarter. Finally, KBC Group NV raised its holdings in Arcutis Biotherapeutics by 43.2% in the 1st quarter. KBC Group NV now owns 4,376 shares of the company's stock valued at $103,000 after acquiring an additional 1,321 shares in the last quarter.

Arcutis Biotherapeutics News Roundup

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Arcutis Biotherapeutics Price Performance

NASDAQ:ARQT opened at $25.55 on Monday. The company has a 50-day moving average of $27.16 and a 200-day moving average of $25.37. The company has a market capitalization of $3.22 billion, a price-to-earnings ratio of 121.67 and a beta of 1.66. Arcutis Biotherapeutics, Inc. has a 52 week low of $19.30 and a 52 week high of $34.80. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.66 and a current ratio of 2.92.

Arcutis Biotherapeutics (NASDAQ:ARQT - Get Free Report) last issued its earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.18 by ($0.12). The business had revenue of $143.92 million for the quarter, compared to analyst estimates of $142.59 million. Arcutis Biotherapeutics had a net margin of 5.88% and a return on equity of 14.18%. As a group, equities research analysts anticipate that Arcutis Biotherapeutics, Inc. will post 0.33 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of analysts have commented on ARQT shares. Needham & Company LLC set a $40.00 price objective on Arcutis Biotherapeutics in a research report on Thursday. Morgan Stanley lifted their price objective on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Wall Street Zen cut Arcutis Biotherapeutics from a "buy" rating to a "hold" rating in a research report on Saturday. Weiss Ratings upgraded Arcutis Biotherapeutics from a "hold (c-)" rating to a "hold (c)" rating in a research report on Thursday, October 29th. Finally, Guggenheim upped their target price on Arcutis Biotherapeutics from $38.00 to $44.00 and gave the company a "buy" rating in a research note on Monday, October 19th. Eight analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Arcutis Biotherapeutics has a consensus rating of "Moderate Buy" and an average target price of $39.75.

Insider Transactions at Arcutis Biotherapeutics

In other Arcutis Biotherapeutics news, EVP Masaru Matsuda sold 40,000 shares of Arcutis Biotherapeutics stock in a transaction that occurred on Wednesday, November 4th. The stock was sold at an average price of $34.32, for a total transaction of $1,372,800.00. Following the sale, the executive vice president directly owned 111,289 shares of the company's stock, valued at approximately $3,819,438.48. The trade was a 26.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Watanabe sold 4,377 shares of the company's stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $139,451.22. Following the completion of the sale, the insider owned 712,826 shares in the company, valued at approximately $22,710,636.36. This represents a 0.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders have sold 123,932 shares of company stock valued at $3,553,077. Corporate insiders own 9.40% of the company's stock.

Arcutis Biotherapeutics Profile

Arcutis Biotherapeutics is a biopharmaceutical company focused on developing and commercializing treatments for inflammatory skin diseases. Founded in 2016, the company is headquartered in Westlake Village, California.

Arcutis primarily serves the U.S.

Want to see what other hedge funds are holding ARQT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.